4.6 Review

Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: A systematic review and meta-analysis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Gastroenterology & Hepatology

Biologics for Inflammatory Bowel Disease and Their Safety Pregnancy: A Systematic Review and Meta-analysis

Ole Haagen Nielsen et al.

Summary: Adverse pregnancy outcomes among pregnant IBD women using biologics are comparable with that of the general population.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Article Gastroenterology & Hepatology

Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease

Uma Mahadevan et al.

Summary: The study found that exposure to biologic, thiopurine, or combination therapy during pregnancy did not increase adverse maternal or fetal outcomes, and these treatments can be continued throughout pregnancy for women with IBD to maintain disease control.

GASTROENTEROLOGY (2021)

Article Dermatology

Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Alexa B. Kimball et al.

Summary: This cohort study reported pregnancy outcomes among women with psoriasis in the Psoriasis Longitudinal Assessment and Registry (PSOLAR), with most pregnancies associated with biologic exposure having similar outcomes to those without biologic exposure.

JAMA DERMATOLOGY (2021)

Article Public, Environmental & Occupational Health

Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden

Gabriella Broms et al.

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)

Article Multidisciplinary Sciences

Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study

Christina D. Chambers et al.

PLOS ONE (2019)

Article Gastroenterology & Hepatology

Pregnancy Outcomes of Patients Exposed to Adalimumab in Japan

Yumi Kawai et al.

DIGESTIVE DISEASES (2019)

Article Gastroenterology & Hepatology

Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti-Tumor Necrosis Factor Agents During Pregnancy

Gabriella Broms et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)

Article Pharmacology & Pharmacy

Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study

Corinna Weber-Schoendorfer et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)

Review Rheumatology

Pregnancy outcomes following exposure to abatacept during pregnancy

Monica Kumar et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)

Article Gastroenterology & Hepatology

Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease

P. Deepak et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

Article Gastroenterology & Hepatology

Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease

M. Seirafi et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)

Article Gastroenterology & Hepatology

Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study

Martin Bortlik et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2013)

Article Gastroenterology & Hepatology

Outcome of Pregnancy in Women with Inflammatory Bowel Disease Treated with Antitumor Necrosis Factor Therapy

Fabian Schnitzler et al.

INFLAMMATORY BOWEL DISEASES (2011)

Review Obstetrics & Gynecology

Preterm birth and low birth weight among in vitro fertilization singletons: A systematic review and meta-analyses

Sarah D. McDonald et al.

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2009)

Review Medicine, General & Internal

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

David Moher et al.

PLOS MEDICINE (2009)

Article Gastroenterology & Hepatology

A meta-analysis on the influence of inflammatory bowel disease on pregnancy

J. Cornish et al.